PT2286794T - Uso de lipossomas catiónicos contendo placlitaxel - Google Patents

Uso de lipossomas catiónicos contendo placlitaxel

Info

Publication number
PT2286794T
PT2286794T PT101807501T PT10180750T PT2286794T PT 2286794 T PT2286794 T PT 2286794T PT 101807501 T PT101807501 T PT 101807501T PT 10180750 T PT10180750 T PT 10180750T PT 2286794 T PT2286794 T PT 2286794T
Authority
PT
Portugal
Prior art keywords
paclitaxel
cationic liposomes
liposomes
cationic
Prior art date
Application number
PT101807501T
Other languages
English (en)
Portuguese (pt)
Inventor
Teifel Michael
Michaelis Uwe
Sauer Birgitta
Bartelheim Kerstin
Brunner Christoph
Original Assignee
Syncore Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncore Biotechnology Co Ltd filed Critical Syncore Biotechnology Co Ltd
Publication of PT2286794T publication Critical patent/PT2286794T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
PT101807501T 2003-10-15 2004-10-15 Uso de lipossomas catiónicos contendo placlitaxel PT2286794T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023539 2003-10-15
EP04000361 2004-01-09

Publications (1)

Publication Number Publication Date
PT2286794T true PT2286794T (pt) 2016-07-13

Family

ID=34524705

Family Applications (1)

Application Number Title Priority Date Filing Date
PT101807501T PT2286794T (pt) 2003-10-15 2004-10-15 Uso de lipossomas catiónicos contendo placlitaxel

Country Status (11)

Country Link
US (1) US20080063699A1 (enExample)
EP (2) EP1673069B1 (enExample)
JP (2) JP5645340B2 (enExample)
AU (1) AU2004283464B8 (enExample)
CA (1) CA2542217C (enExample)
DK (1) DK2286794T3 (enExample)
ES (1) ES2574231T3 (enExample)
HU (1) HUE028648T2 (enExample)
PL (1) PL2286794T3 (enExample)
PT (1) PT2286794T (enExample)
WO (1) WO2005039533A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
SG166775A1 (en) 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2601067A1 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
RU2444351C2 (ru) * 2005-09-01 2012-03-10 Биолипокс Аб Композиция для лечения ринита и родственных заболеваний и способ ее получения
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
KR100658436B1 (ko) * 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
BRPI0709075A2 (pt) * 2006-03-20 2011-10-11 Medigene Ag tratamento de cáncer de mama triplo receptor negativo
US20090232731A1 (en) * 2006-05-18 2009-09-17 Martin Funk Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US9144575B2 (en) 2010-07-28 2015-09-29 Life Technologies Corporation Anti-viral azide containing compounds
JP6112512B2 (ja) * 2010-12-01 2017-04-12 レクシ ファーマ インコーポレイテッド 難治性癌を治療するための方法
MX360823B (es) 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
CN108977412A (zh) 2012-01-26 2018-12-11 生命科技公司 用于提高病毒感染性的方法
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
JP6484558B2 (ja) 2012-11-28 2019-03-13 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーBiontech Rna Pharmaceuticals Gmbh 癌ワクチンの組み合せ物
DE102013009744A1 (de) * 2013-03-26 2014-10-02 Forschungszentrum Jülich GmbH Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA3026454C (en) 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
CN114588270B (zh) 2015-09-16 2024-08-06 Dfb索里亚有限责任公司 包含紫杉烷类纳米颗粒的组合物及其用途
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
KR20190084284A (ko) * 2016-11-11 2019-07-16 웨스턴 유니버시티 오브 헬스 사이언시스 상부요로상피암종의 치료 방법
TWI852903B (zh) * 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
KR102303762B1 (ko) 2017-06-14 2021-09-23 크리티테크, 인크. 폐 장애의 치료 방법
WO2019070850A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
WO2024160190A1 (zh) * 2023-01-31 2024-08-08 石药集团中奇制药技术(石家庄)有限公司 紫杉醇阳离子脂质体治疗肿瘤的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
ATE194767T1 (de) 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
DE4447770C2 (de) * 1994-08-20 2002-12-19 Max Delbrueck Centrum Verfahren zur Herstellung von liposomal verkapseltem Taxol
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US7314637B1 (en) * 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
JP4848113B2 (ja) * 1999-09-09 2011-12-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血管新生血管に対するタキサンの陽イオン性リポソーム送達
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
AU2003249882B2 (en) * 2002-06-26 2008-09-18 Medigene Ag Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
WO2004002468A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound

Also Published As

Publication number Publication date
AU2004283464B2 (en) 2011-03-17
EP2286794A1 (en) 2011-02-23
JP2012229255A (ja) 2012-11-22
WO2005039533A1 (en) 2005-05-06
ES2574231T3 (es) 2016-06-16
PL2286794T3 (pl) 2016-10-31
US20080063699A1 (en) 2008-03-13
JP5645340B2 (ja) 2014-12-24
EP2286794B8 (en) 2016-06-01
CA2542217A1 (en) 2005-05-06
AU2004283464A1 (en) 2005-05-06
EP1673069A1 (en) 2006-06-28
HUE028648T2 (en) 2016-12-28
DK2286794T3 (en) 2016-07-25
JP2007508353A (ja) 2007-04-05
EP2286794B1 (en) 2016-03-30
CA2542217C (en) 2018-03-27
AU2004283464B8 (en) 2011-04-14
EP1673069B1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
PL2286794T3 (pl) Zastosowanie kationowych liposomów zawierających paklitaksel
GB0312309D0 (en) Targeted liposome
IL173478A0 (en) Form of administration secured against misuse
EP1614386A4 (en) ECHOGRAPHIC APPARATUS
EP1623696A4 (en) COSMETIC PREPARATION ON OIL BASIS
GB0415345D0 (en) Alternating voided areas of anti-pads
GB0305150D0 (en) Use of therapeutic compounds
EP1645265A4 (en) COSMETIC PREPARATION ON OIL BASIS
ZA200602386B (en) 5-Arylpyrimidines as anticancer agents
GB0519079D0 (en) Asthma preperation
EP1658274A4 (en) INHIBITORS OF CATHEPSIN S
IL173851A0 (en) Therapeutic liposomes
GB0327742D0 (en) Novel uses of known drugs
EP1677782A4 (en) INHIBITORS OF CATHEPSIN S
PL377902A1 (pl) Nowe zastosowanie kompleksu fosfor-azot-metal
IL172407A0 (en) Dna-based aptamers for human cathepsin g
GB2399559B (en) Construction of container
EP1809245A4 (en) THERAPEUTIC LIPOSOME
PL378419A1 (pl) Kombinacja leków przeciwcukrzycowych
AU2003261103A8 (en) Compounds promoting delivery of genes
TW561865U (en) Improvement of curtain
GB0313027D0 (en) Mxximus chest protector
SI2108362T1 (sl) Kationski nosilni sistem, ki vsebuje taksan
GB0307824D0 (en) Treatment of dyskinesia
TW553243U (en) Structure of clotheshanger